Status:
TERMINATED
CPCT-05 Biopsy Protocol Patient Selection
Lead Sponsor:
P.O. Witteveen
Collaborating Sponsors:
The Netherlands Cancer Institute
Erasmus Medical Center
Conditions:
Solid Tumors
Metastatic Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Our knowledge on the genetic mutations in cancer is rapidly expanding and we are increasingly testing drugs in mainly metastatic cancer patient populations with rare mutations. Successful examples of ...
Eligibility Criteria
Inclusion
- Locally advanced (incurable) or metastatic cancer from a histological or cytological proven solid tumor
- Indication for systemic treatment with anti-cancer agents (with no treatment options with curative intent)
- Measurable locally advanced (incurable) or metastatic lesion(s), according to RECIST 1.1 criteria.
- Safe biopsy of a metastatic or locally advanced lesion possible
- No contraindications for lidocaine (or its derivatives) and/or midazolam and/or phentanyl
- Adequate organ function
- WHO performance status 0-2
- Age \> 18 yr
- Expected adequacy to follow up
- Written informed consent
Exclusion
- • If one or more of the above mentioned inclusion criteria is not met
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT01904916
Start Date
January 1 2014
End Date
March 1 2017
Last Update
March 9 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
2
Erasmus Medical Center
Rotterdam, Netherlands
3
University Medical Center Utrecht
Utrecht, Netherlands, 3508 GX